The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 27, 2022
Filed:
Nov. 30, 2015
Applicant:
Crage Medical Co., Limited, Kowloon, HK;
Inventors:
Huamao Wang, Shanghai, CN;
Xiumei Cai, Shanghai, CN;
Hongxia Zhao, Shanghai, CN;
Bo Song, Shanghai, CN;
Yuanmei Chen, Shanghai, CN;
Yinyu Zhu, Shanghai, CN;
Assignee:
CRAGE MEDICAL CO., LIMITED, Mongkok Kowloon, HK;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); C12N 5/10 (2006.01); A61K 39/395 (2006.01); C12N 15/63 (2006.01); C07K 14/00 (2006.01); C07K 16/28 (2006.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C07K 16/30 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0636 (2013.01); A61K 35/17 (2013.01); A61K 39/395 (2013.01); A61P 35/00 (2018.01); C07K 14/00 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/28 (2013.01); C07K 16/2851 (2013.01); C07K 16/303 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2740/15043 (2013.01);
Abstract
Provided are a GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof. The cell is an immune effector cell capable of identifying the gene modification of GPC3 and ASGPR1 simultaneously, and the cell can be used in the treatment of GPC3 and ASGPR1 double positive tumours, such as liver cancer.